相似文献
1
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
2
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.
3
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases.
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):754-759. Epub 2020 Jul 28.
4
[Dealing with COVID-19-associated coagulopathy].
Ned Tijdschr Geneeskd. 2020 Apr 15;164:D5031.
5
Severe COVID-19 infection associated with endothelial activation.
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
6
Cautious interpretation of antiphospholipid antibodies in COVID-19.
Clin Chim Acta. 2020 Oct;509:166. doi: 10.1016/j.cca.2020.06.024. Epub 2020 Jun 15.
7
[Coagulopathy and COVID-19. Recommendations for a changing reality].
Medicina (B Aires). 2020;80(5):505-511.
8
Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19.
Circ Res. 2020 Jul 17;127(3):400-401. doi: 10.1161/CIRCRESAHA.120.317173. Epub 2020 Jun 8.
9
Coagulopathy associated with COVID-19.
CMAJ. 2020 May 25;192(21):E583. doi: 10.1503/cmaj.200685. Epub 2020 May 1.
10
Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19).
JAMA Netw Open. 2020 Aug 3;3(8):e2017539. doi: 10.1001/jamanetworkopen.2020.17539.
引用本文的文献
1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.
Front Med (Lausanne). 2025 Aug 6;12:1588062. doi: 10.3389/fmed.2025.1588062. eCollection 2025.
3
Comparative immunological study of Plasmodium knowlesi infections in humans and macaques: insights into cytokine dynamics.
Malar J. 2025 Jul 16;24(1):233. doi: 10.1186/s12936-025-05478-4.
4
Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection.
Stem Cells Transl Med. 2025 Jun 25;14(7). doi: 10.1093/stcltm/szaf025.
5
Increased Anticoagulant Requirement in Total Hip Replacement Patients Post-COVID: A Comparative Study in the Indian Population.
J Orthop Case Rep. 2025 Jul;15(7):222-230. doi: 10.13107/jocr.2025.v15.i07.5832.
6
Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?
Front Immunol. 2025 Jun 19;16:1599639. doi: 10.3389/fimmu.2025.1599639. eCollection 2025.
7
COVID-19-Related Pathologies in Coronary Angiography in Patients with Acute Coronary Syndromes.
J Clin Med. 2025 May 23;14(11):3672. doi: 10.3390/jcm14113672.
8
Post-COVID-19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies.
J Pathol. 2025 Aug;266(4-5):369-389. doi: 10.1002/path.6443. Epub 2025 Jun 10.
9
COVID-19 coagulopathy and antiphospholipid syndrome.
Rev Colomb Reumatol. 2022 Jun;29:S25-S34. doi: 10.1016/j.rcreu.2021.02.013. Epub 2021 Aug 27.
10
d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection.
Rev Colomb Reumatol. 2022 Jun;29:S84-S87. doi: 10.1016/j.rcreu.2021.06.003. Epub 2021 Jul 5.
本文引用的文献
1
Viral infections and antiphospholipid antibodies.
Semin Arthritis Rheum. 2002 Feb;31(4):256-63. doi: 10.1053/sarh.2002.28303.
Zotero 插件